연세대학교 · Medicine
Hye Ryun Kim 교수의 연구실은 비만, 면역세포 기반 바이오마커 및 종양 미세환경을 중심으로 암의 예후 및 치료 반응을 규명하는 데 초점을 맞추고 있습니다. 특히 헤드 앤 넥 스퀨머스 세포 암, 비소세포성 폐암 등에서 면역관문 억제제 반응 예측 및 타겟 치료 전략 개발을 위한 분자 기반 연구를 진행하고 있습니다. FGFR1 확장, PD-L1 발현, 조혈세포 유래 억제성 세포 등 암의 면역 회피 기전을 규명하고 있으며, 신약 개발과 맞춤형 치료 전략 수립을 목표로 하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
To investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints and their prognostic value for resected head and neck squamous cell cancer (HNSCC). PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC), abundance of tumor-infiltrating lymphocytes (TILs), and expression of the immune checkpoints were investigated in 402 HNSCC patients. PD-L1 expression on TC and IC was categorized into four groups according to the percentage of PD-L1-positive cell
FGFR1 amplification is an independent negative prognostic factor in surgically resected SCCL and is associated with cigarette smoking in a dose-dependent manner. FGFR1 amplification is a relevant therapeutic target in Asian patients with SCCL.
To the authors' knowledge, this was the largest comprehensive and concurrent analysis to date of 3 major oncogenic alterations in a cohort of East Asian never-smokers with NSCLC. Because survival outcomes differed among genotypes, and drugs that target specific alterations currently are available, genetic profiling to identify genotype-specific subsets can lead to successful treatment with appropriate kinase inhibitors.
Our findings suggest that YH25448 is a promising third-generation EGFR inhibitor, which may be more effective and better tolerated than the currently approved osimertinib.
title: The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer, doi: 10.1164/rccm.201808-1502LE, category: Article
We demonstrate that the TME confers a suppressive function on T<sub>reg</sub> cells by upregulating IC-molecule expression. Targeting IC-molecules, including PD-1, on T<sub>reg</sub> cells may be effective for cancer treatment.
